FSHR rs7747753: Promoter Genetics and Ovarian Response
The rs7747753 variant is a well-studied single nucleotide polymorphism located in the promoter region of the follicle-stimulating hormone receptor (FSHR) gene, frequently designated as -29G>A. It is primarily evaluated for its association with ovarian sensitivity to gonadotropins during controlled ovarian stimulation in assisted reproductive technologies like in vitro fertilization (IVF). Research indicates that this variant may modulate promoter transcription and alter drug requirements, though current clinical evidence remains limited and variable across different populations.
What each genotype means
Typical FSH receptor expression
You carry two copies of the G allele (historically referred to as -29G in promoter studies). Research suggests this baseline genotype maintains typical FSH receptor promoter activity and standard ovarian responsiveness during assisted reproductive therapies like IVF. However, because overall evidence linking promoter variations to ovarian stimulation outcomes remains limited and mixed across studies, you should always discuss any fertility medication protocols or gonadotropin dosing directly with your reproductive endocrinologist.
Carried by approximately 27% to 36% of individuals across global populations, being most common in East Asian ancestries.
Intermediate promoter activity
You carry one copy of the A allele and one copy of the G allele. In vitro and clinical observational studies suggest this heterozygous genotype is associated with intermediate FSH receptor expression and average gonadotropin sensitivity during controlled ovarian stimulation. Because clinical evidence is limited and non-genetic factors play a substantial role in ovarian response, any individualized medication planning should be determined in consultation with your clinician or pharmacist.
Carried by approximately 48% to 50% of individuals worldwide, representing the most common genotype across most ancestral cohorts.
Altered FSH receptor response
You carry two copies of the A allele (frequently noted in reproductive literature as -29A or -29A/A). Some studies indicate this genotype is correlated with reduced promoter transcriptional activity, which may relate to lower sensitivity to follicle-stimulating hormone and higher requirement for exogenous gonadotropins during IVF protocols. Because evidence remains limited and conflicting between study cohorts, never adjust any prescribed fertility medications independently and review all dosing decisions with your healthcare provider.
Carried by approximately 16% to 23% of individuals globally, observed slightly more frequently in European and African populations.
Genetic Architecture and Molecular Location
The single nucleotide polymorphism rs7747753 is located on human chromosome 2 within the 5-prime upstream promoter region of the follicle-stimulating hormone receptor (FSHR) gene. In classic reproductive literature, this variant is widely documented under the functional designation -29G>A, representing a single base change upstream of the translation start site. Because it sits in the core promoter rather than the protein-coding sequence, rs7747753 does not modify the structural amino acid sequence of the receptor itself. Instead, functional laboratory assays suggest that the nucleotide change influences transcriptional activity by altering binding affinities for regulatory transcription factors. Specifically, molecular studies indicate that the A allele can decrease transcriptional promoter efficiency relative to the ancestral G allele. This reduced expression may lower the density of follicle-stimulating hormone receptors displayed on the surface of target ovarian granulosa cells, altering downstream cellular signaling.
Biological Role of the FSHR Pathway
The FSHR gene encodes a transmembrane G-protein coupled receptor that serves as the exclusive receptor for follicle-stimulating hormone (FSH), a pituitary glycoprotein essential for human gametogenesis. In females, FSH receptors are expressed almost exclusively on the surface of ovarian granulosa cells surrounding developing follicles. When endogenous FSH or therapeutic gonadotropins bind to this receptor, they activate intracellular cyclic AMP (cAMP) and protein kinase cascades. These pathways promote follicle maturation, stimulate aromatase enzyme expression for estrogen biosynthesis, and prevent follicular atresia. In males, FSHR expression on testicular Sertoli cells supports normal spermatogenesis. Because follicular development relies on a fine-tuned hormonal threshold, variations in receptor density or signaling efficacy—such as those influenced by promoter variants like rs7747753—can modify how ovarian tissue perceives and reacts to circulating FSH levels.
Research Findings and Clinical Evidence Strength
Scientific evaluation of rs7747753 has centered largely on reproductive endocrinology and assisted reproductive technology outcomes. Clinical studies exploring women undergoing controlled ovarian hyperstimulation for IVF have assessed whether carriers of the A allele experience altered sensitivity to exogenous gonadotropins. Some observational investigations suggest that individuals with the AA or AG genotypes display a reduced ovarian response, reflected by higher total gonadotropin dose requirements, slightly lower peak estradiol levels, or fewer retrieved oocytes. However, the evidence strength supporting rs7747753 as an independent clinical predictor remains limited and mixed. Multiple replication studies and meta-analyses have found inconsistent results, demonstrating that baseline ovarian reserve markers—such as anti-Müllerian hormone (AMH) and antral follicle count (AFC)—remain far more clinically predictive than single promoter variants. Furthermore, strong linkage disequilibrium with coding SNPs like rs6165 and rs6166 complicates the isolation of its independent effect.
Interpreting Results in Clinical Context
Understanding an rs7747753 genotype provides biological insight into personal genetic variation, but it does not constitute a diagnostic test or a clinical roadmap. Individuals cannot use this genotype alone to diagnose infertility, determine reproductive potential, or predict IVF success. If you are preparing for assisted reproductive treatments or ovulation induction, gonadotropin dosing and protocol selection must always be directed by your reproductive endocrinologist using standard clinical diagnostics, including AMH testing, ultrasound follicular monitoring, and clinical history. Prospective patients should never attempt to adjust prescribed medications or anticipate specific cycle outcomes based on consumer genetic tests. While pharmacogenomic research continues to investigate multi-marker models for personalized ovarian stimulation, rs7747753 serves currently as an educational marker rather than an actionable guide for standalone clinical care.
How common is this variant?
The rs7747753 minor allele is widely distributed worldwide, with observed minor allele frequencies typically ranging between 0.40 and 0.48 across diverse ancestral populations in global genomic datasets.
Frequently asked questions
Does having the rs7747753 A allele cause infertility?
No, having the A allele at rs7747753 does not cause infertility. It is a common natural variation found in roughly 40% to 48% of alleles worldwide and is associated only with subtle statistical shifts in receptor density and ovarian sensitivity. Most individuals carrying this variant conceive naturally without reproductive difficulties.
What is the difference between rs7747753 and the -29G>A notation?
They refer to the exact same genetic variant. The label rs7747753 is the official identifier assigned by the dbSNP database, whereas -29G>A is the historical nomenclature used in reproductive medicine literature to indicate that the substitution occurs 29 base pairs upstream of the FSHR start codon.
Can this genetic test determine my IVF medication dosage?
No, this genetic variant cannot be used independently to calculate or alter your medication dosage. In vitro fertilization protocols rely primarily on validated clinical parameters, including anti-Müllerian hormone (AMH) levels, antral follicle counts, age, and previous ovarian response. Any medication decisions must be made directly with your fertility specialist.
How does rs7747753 relate to other FSHR variants like rs6165 or rs6166?
The rs7747753 variant is located in the promoter region of the FSHR gene, whereas rs6165 (Thr307Ala) and rs6166 (Asn680Ser) are located within the coding sequence. These variants are frequently inherited together in haplotypes due to linkage disequilibrium, which can make it challenging for researchers to isolate the distinct clinical effect of rs7747753 alone.
Sources & further reading
Educational information only, last refreshed 9/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7747753?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FSHR
Rare variant neighboring key follicle-stimulating hormone receptor regulatory sequences evaluated for impact on gametogenesis.
Variant in the follicle-stimulating hormone receptor (FSHR) promoter region that influences basal FSH levels and ovarian response to gonadotropin stimulation during reproductive cycles.
Located in the promoter region (-29 G>A) of the follicle-stimulating hormone receptor gene, this variant modulates FSHR expression levels and alters ovarian response during controlled ovarian hyperstimulation.
Common non-coding regulatory variant in the follicle stimulating hormone receptor locus influencing ovarian sensitivity and gonadotropin dosage requirements.
Variant in the follicle stimulating hormone receptor gene associated with altered ovarian response and exogenous gonadotropin requirements in controlled ovarian stimulation.
Loss-of-function missense variant in FSHR causing ovarian hypergonadotropic hypogonadism and ovarian dysgenesis.